Aspen Neuroscience, a Parkinson’s cell-therapy developer, filed to go public and is seeking Nasdaq listing with funds earmarked for its lead program. The approach aims to turn a patient’s own cells into dopamine-producing neurons, placing the company among the newer category of autologous or patient-cell platforms targeting neurodegeneration. For investors, the filing signals continued capital demand for early-stage regenerative neuroscience programs as timelines to clinical proof remain a central valuation driver.